O	0	3	The
O	4	14	prevalence
O	15	17	of
O	18	39	immunohistochemically
O	40	50	determined
O	51	60	oestrogen
O	61	69	receptor
O	70	80	positivity
O	81	83	in
O	84	91	primary
O	92	98	breast
O	99	105	cancer
O	106	108	is
O	109	118	dependent
O	119	121	on
O	122	125	the
O	126	132	choice
O	133	135	of
O	136	144	antibody
O	145	148	and
O	149	155	method
O	156	158	of
O	159	163	heat
O	163	164	-
O	164	171	induced
O	172	179	epitope
O	180	189	retrieval
O	190	191	-
O	192	202	prognostic
O	203	215	implications
O	215	216	?

O	217	226	Oestrogen
O	227	235	receptor
O	236	237	(
O	237	239	ER
O	239	240	)
O	241	247	status
O	248	250	is
O	251	260	important
O	261	264	for
O	265	268	the
O	269	275	choice
O	276	278	of
O	279	287	systemic
O	288	297	treatment
O	298	300	of
O	301	307	breast
O	308	314	cancer
O	315	323	patients
O	323	324	.

O	325	332	However
O	332	333	,
O	334	338	most
O	339	343	data
O	344	348	from
O	349	359	randomised
O	360	366	trials
O	367	369	on
O	370	373	the
O	374	380	effect
O	381	383	of
O	384	392	adjuvant
O	393	402	endocrine
O	403	410	therapy
O	411	420	according
O	421	423	to
O	424	426	ER
O	427	433	status
O	434	437	are
O	438	443	based
O	444	446	on
O	447	450	the
O	451	458	cytosol
O	459	466	methods
O	466	467	.

O	468	479	Comparisons
O	480	484	with
O	485	504	immunohistochemical
O	505	512	methods
O	513	517	have
O	518	523	given
O	524	531	similar
O	532	539	results
O	539	540	.

O	541	544	The
O	545	548	aim
O	549	551	of
O	552	555	the
O	556	563	present
O	564	569	study
O	570	573	was
O	574	576	to
O	577	584	examine
O	585	592	whether
O	593	602	different
O	603	605	ER
O	606	616	antibodies
O	617	620	and
O	621	625	heat
O	625	626	-
O	626	633	induced
O	634	641	epitope
O	642	651	retrieval
O	652	653	(
O	653	657	HIER
O	657	658	)
O	659	666	methods
O	667	676	influence
O	677	680	the
O	681	691	prevalence
O	692	694	of
O	695	697	ER
O	697	698	-
O	698	708	positivity
O	709	711	in
O	712	719	primary
O	720	726	breast
O	727	733	cancer
O	733	734	.

O	735	739	This
O	740	745	study
O	746	748	is
O	749	754	based
O	755	757	on
O	758	766	patients
O	767	775	included
O	776	778	in
O	779	780	a
O	781	789	clinical
O	790	795	trial
O	796	804	designed
O	805	807	to
O	808	815	compare
O	816	819	the
O	820	826	effect
O	827	829	of
O	830	833	two
O	834	839	years
O	840	842	of
B-intervention	843	851	adjuvant
I-intervention	852	861	tamoxifen
O	862	868	versus
O	869	871	no
B-control	872	880	adjuvant
I-control	881	889	systemic
I-control	890	899	treatment
O	900	902	in
B-eligibility	903	916	premenopausal
I-eligibility	917	922	women
O	922	923	.

O	924	928	From
O	929	933	1986
O	934	936	to
O	937	941	1991
O	941	942	,
B-total-participants	943	946	564
O	947	955	patients
O	956	960	from
O	961	964	two
O	965	970	study
O	971	978	centres
O	979	981	in
B-location	982	988	Sweden
O	989	993	were
O	994	1002	enrolled
O	1003	1006	and
O	1007	1017	randomised
O	1017	1018	.

O	1019	1027	Patients
O	1028	1032	were
O	1033	1043	randomised
O	1044	1057	independently
O	1058	1060	of
O	1061	1063	ER
O	1064	1070	status
O	1070	1071	.

O	1072	1074	In
O	1075	1078	the
O	1079	1086	present
O	1087	1092	study
O	1092	1093	,
O	1094	1096	ER
O	1097	1103	status
O	1104	1107	was
O	1108	1116	assessed
O	1117	1119	on
O	1120	1126	tissue
O	1127	1138	microarrays
O	1139	1143	with
O	1144	1147	the
O	1148	1153	three
O	1154	1163	different
O	1164	1166	ER
O	1167	1175	antibody
O	1175	1176	/
O	1176	1180	HIER
O	1181	1193	combinations
O	1193	1194	:
O	1195	1198	1D5
O	1199	1201	in
O	1202	1209	citrate
O	1210	1212	pH
O	1213	1214	6
O	1215	1216	(
O	1216	1217	n
O	1218	1219	=
B-intervention-participants	1220	1223	390
O	1223	1224	)
O	1224	1225	,
O	1226	1229	SP1
O	1230	1232	in
O	1233	1237	Tris
O	1238	1240	pH
O	1241	1242	9
O	1243	1244	(
O	1244	1245	n
O	1246	1247	=
B-intervention-participants	1248	1251	390
O	1251	1252	)
O	1253	1256	and
O	1257	1264	PharmDx
O	1265	1267	in
O	1268	1275	citrate
O	1276	1278	pH
O	1279	1280	6
O	1281	1282	(
O	1282	1283	n
O	1284	1285	=
B-intervention-participants	1286	1289	361
O	1289	1290	)
O	1290	1291	.

O	1292	1294	At
O	1295	1298	cut
O	1298	1299	-
O	1299	1303	offs
O	1304	1306	of
O	1307	1308	1
O	1308	1309	%
O	1310	1313	and
O	1314	1316	10
O	1316	1317	%
O	1317	1318	,
O	1319	1331	respectively
O	1331	1332	,
O	1333	1336	the
B-outcome	1337	1347	prevalence
I-outcome	1348	1350	of
I-outcome	1351	1353	ER
I-outcome	1353	1354	-
I-outcome	1354	1364	positivity
O	1365	1368	was
O	1369	1375	higher
O	1376	1380	with
O	1381	1384	SP1
O	1385	1386	(
B-iv-bin-percent	1386	1388	75
I-iv-bin-percent	1388	1389	%
O	1390	1393	and
B-iv-bin-percent	1394	1396	72
I-iv-bin-percent	1396	1397	%
O	1397	1398	)
O	1399	1407	compared
O	1408	1412	with
O	1413	1416	1D5
O	1417	1418	(
B-iv-bin-percent	1418	1420	68
I-iv-bin-percent	1420	1421	%
O	1422	1425	and
B-iv-bin-percent	1426	1428	66
I-iv-bin-percent	1428	1429	%
O	1429	1430	)
O	1431	1434	and
O	1435	1442	PharmDx
O	1443	1444	(
B-iv-bin-percent	1444	1446	66
I-iv-bin-percent	1446	1447	%
O	1448	1451	and
B-iv-bin-percent	1452	1454	62
I-iv-bin-percent	1454	1455	%
O	1455	1456	)
O	1456	1457	.

O	1458	1460	At
O	1461	1466	these
O	1467	1470	cut
O	1470	1471	-
O	1471	1475	offs
O	1475	1476	,
O	1477	1485	patients
O	1486	1488	in
O	1489	1492	the
O	1493	1503	discordant
O	1504	1510	groups
O	1511	1512	(
O	1512	1515	SP1
O	1515	1516	-
O	1516	1524	positive
O	1525	1528	and
O	1529	1532	1D5
O	1532	1533	-
O	1533	1541	negative
O	1541	1542	)
O	1543	1547	seem
O	1548	1550	to
O	1551	1555	have
O	1556	1557	a
O	1558	1567	prognosis
O	1568	1580	intermediate
O	1581	1588	between
O	1589	1594	those
O	1595	1597	of
O	1598	1601	the
O	1602	1608	double
O	1608	1609	-
O	1609	1617	positive
O	1618	1621	and
O	1622	1628	double
O	1628	1629	-
O	1629	1637	negative
O	1638	1644	groups
O	1644	1645	.

O	1646	1656	Comparison
O	1657	1661	with
O	1662	1665	the
O	1666	1668	ER
O	1669	1675	status
O	1676	1686	determined
O	1687	1689	by
O	1690	1693	the
O	1694	1701	cytosol
O	1701	1702	-
O	1702	1707	based
O	1708	1715	methods
O	1716	1718	in
O	1719	1722	the
O	1723	1733	discordant
O	1734	1739	group
O	1740	1744	also
O	1745	1751	showed
O	1752	1754	an
O	1755	1767	intermediate
O	1768	1775	pattern
O	1775	1776	.

O	1777	1780	The
O	1781	1794	repeatability
O	1795	1798	was
O	1799	1803	good
O	1804	1807	for
O	1808	1811	all
O	1812	1822	antibodies
O	1823	1826	and
O	1827	1830	cut
O	1830	1831	-
O	1831	1835	offs
O	1835	1836	,
O	1837	1841	with
O	1842	1849	overall
O	1850	1859	agreement
O	1860	1861	â‰¥
O	1862	1864	93
O	1864	1865	%
O	1865	1866	.

O	1867	1870	The
O	1871	1878	present
O	1879	1884	study
O	1885	1890	shows
O	1891	1895	that
O	1896	1899	the
O	1900	1906	choice
O	1907	1909	of
O	1910	1918	antibody
O	1919	1922	and
O	1923	1927	HIER
O	1928	1934	method
O	1935	1945	influences
O	1946	1949	the
O	1950	1960	prevalence
O	1961	1963	of
O	1964	1966	ER
O	1966	1967	-
O	1967	1977	positivity
O	1977	1978	.

O	1979	1981	We
O	1982	1989	suggest
O	1990	1994	that
O	1995	1999	this
O	2000	2002	be
O	2003	2008	taken
O	2009	2013	into
O	2014	2027	consideration
O	2028	2032	when
O	2033	2041	choosing
O	2042	2043	a
O	2044	2047	cut
O	2047	2048	-
O	2048	2051	off
O	2052	2055	for
O	2056	2064	clinical
O	2065	2073	decision
O	2074	2080	making
O	2080	2081	.
